Also listed on Saliogen Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends May 4, 2041 · High confidence
20-year base term ends May 4, 2041
May 4, 2021
May 4, 2041
May 28, 2024
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 4, 2021, when application PCT/US2021/030729, the earliest non-provisional in its chain, was filed (this one was filed Mar 29, 2023) | May 4, 2041 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,542,528) | resolves to May 4, 2041, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 4, 2041 | High confidence |
This family
| Application PCT/US2021/030729 | PCT application no patent term | no patent term |
| US 11,542,528 | In force May 2041 | May 2041 |
| Application 18/058,486 | Pending not computed | not computed |
| US 11,993,784 | this patent May 2041 | May 2041 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 7, 2023 Reel 63256, frame 662 | Higgins, Joseph J.; Tabibiazar, Ray | Saliogen Therapeutics, Inc. | Assignment of Assignor's Interest |
| Apr 7, 2023 Reel 63256, frame 672 | McMillan, Scott | Saliogen Therapeutics, Inc. | Assignment of Assignor's Interest |
| Feb 13, 2026 Reel 73782, frame 623 | Saliogen Therapeutics, Inc. | Blue Marlin Therapeutics, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 11,542,528, ends no earlier than this term, so it caps nothing.